Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance

1st Edition - June 22, 2022
Imprint: Elsevier
Editors: Muthupandian Saravanan, Hamed Barabadi, Ebrahim Mostafavi, Thomas J Webster
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 7 9 2 - 7
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 8 1 0 - 9

Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance focuses on recent and emerging trends surrounding nanomaterials and nano-drug… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance focuses on recent and emerging trends surrounding nanomaterials and nano-drug delivery approaches to combat antimicrobial resistance. The relationship between nanomaterials and antimicrobial activity needs to be deeply explored to meet the challenges of combating antimicrobial resistance. The content of this book is divided into three main topic areas, including (i) how to overcome the existing traditional approaches to combat antimicrobial resistance, (ii) applying multiple drug delivery mechanisms to target multi-drug resistant microbes, and (iii) how nanomaterials can be used as drug carriers.

This is an important reference source for those looking to understand how nanotechnology plays an important role in combatting disease and infection. As antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi, this is a timely resource.

Cover Image
Title Page
Copyright
Table of Contents
Contributors
Editors’ biography
Preface
Chapter 1 Novel medicinal and synthetic chemistry strategies against antimicrobial resistance
1.1 Introduction
1.2 β-lactam antibiotics
1.3 Macrolide antibiotics
1.4 Aminoglycosides
1.5 Quinolones
1.6 Tetracyclines
1.7 Novel strategies and scaffolds beyond the conventional antibiotics
1.8 Conclusion
References
Chapter 2 Strategies of surface engineering/modifications for reversing antibiotic resistance
2.1 Introduction
2.2 Antibiotic and infection control
2.3 Antibacterial resistance mechanisms
2.4 Clinical significance of AMR
2.5 Potential intrinsic antibacterial nanomaterials
2.6 Combination of antibiotics and nanomaterials
2.7 Physicochemical modifications of nanomaterials to combat AR
2.8 Nanomaterials for prevention of biofilm formation
2.9 Targeting antimicrobial agents to infections using nanomaterials
2.10 Conclusions and future perspectives
References
Chapter 3 Overcoming antimicrobial resistance by nanoparticles
3.1 Introduction
3.2 Lipid-based NPs
3.3 Polymer-based NPs
3.4 Dendrimers
3.5 Metal-based NPs
3.6 Carbon-based NPs
3.7 Cyclodextrin NPs
3.8 Conclusion
References
Chapter 4 Nano-targeted drug delivery approaches for biofilm-associated infections
4.1 Introduction
4.2 Biofilm associated infections
4.3 Nanotechnology in the management of biofilm-associated infections
4.4 Nano-targeted drug delivery approaches in particular biofilm-associated diseases
4.5 Discussion and conclusions
4.6 Funding
4.7 Acknowledgments
4.8 Conflicts of interest
References
Chapter 5 Nano-targeted drug delivery approaches for bacterial infections
5.1 Introduction
5.2 Common bacterial infections
5.3 Targeted nano-based drug delivery systems for antibacterial therapy
5.4 Challenges and future perspective
5.5 Conclusion
List of acronyms and abbreviations
References
Chapter 6 Nanostructured drug delivery approaches for fungal infections
6.1 Introduction
6.2 Lipid-based nanoparticles
6.3 Polymer-based nanoparticles
6.4 Nanosuspensions and nanocrystals
6.5 Inorganic nanoparticles
6.6 Nanofibers
6.7 Other nanostructures
6.8 Conclusion and future directions
References
Chapter 7 Nano-targeted drug delivery approaches for viral infections
7.1 Introduction
7.2 Nanomaterials and their application for antiviral therapeutics
7.3 Types of antiviral therapeutic nanoparticles
7.4 Targeted delivery of nanoparticles for antiviral agents
7.5 Limitations of nanoparticles as antiviral therapeutics
7.6 Conclusion
References
Chapter 8 Biogenic metal nanomaterials to combat antimicrobial resistance
8.1 Antimicrobial resistance to antibiotics (AMR)
8.2 Nanotechnology to combat AMR
8.3 Biogenic nanomaterials to fight AMR
8.4 Conclusions
References
Chapter 9 Nanotechnology-based approaches against COVID-19
9.1 Introduction
9.2 Nanotechnology in the control and prevention of coronavirus infections
9.3 Nanotechnology in the detection of coronavirus infections
9.4 Nanotechnology in the treatment of coronavirus infections
9.5 COVID-19 nanovaccines
9.6 Biomimetic engineering of artificial viruses
9.7 Commercialization
9.8 Conclusion
References
Chapter 10 Nanotechnology-based approaches for antitubercular drug delivery
10.1 Introduction to tuberculosis
10.2 Drugs used for TB treatment
10.3 Nanoparticles as antimicrobial agents
10.4 Nanotechnology approaches for TB drug delivery
10.5 Hurdles and limitations for nanotechnology as a future TB therapy
10.6 Conclusion and recommendation
References
Chapter 11 Nano-targeted drug delivery for parasitic infections
11.1 Introduction
11.2 Parasitic infection in the world
11.3 Different nano-based drug delivery system in parasitic infections (helminths and protozoa)
11.4 Transport and distribution of nano-loaded drugs
11.5 Future prospects
References
Chapter 12 Nanovaccines delivery approaches against infectious diseases
12.1 Introduction
12.2 Different types of vaccines for infection diseases
12.3 Routs of vaccine administration
12.4 Vaccines delivery challenges and advantages of nanotechnology in this regard
12.5 Nanotechnology-based delivery of vaccines
12.6 Approved nanodelivery vehicles in commercial vaccine products
12.7 Dendritic cell-targeted nanovaccine delivery system
12.8 Nanoparticles as adjuvants in vaccine delivery
12.9 Challenges and outlooks of nanovaccines
References
Chapter 13 Nanotechnology-based therapies for skin wound regeneration
13.1 Introduction
13.2 Normal wound healing process
13.3 Nanotechnology in wound healing
13.4 Smart wound healing dressings
Concluding remarks and future perspectives
List of acronyms and abbreviations
References
Chapter 14 Photodynamic therapy with nanomaterials to combat microbial infections
14.1 Introduction
14.2 Use of nanoparticles for aPDT
14.3 Supramolecular assembly
14.4 Upconversion nanoparticles as photosensitizers
14.5 Nanotechnology base application for dental caries through antibacterial approach
14.6 Future research direction
14.7 Conclusion
References
Chapter 15 Application of extracellular vesicles in the diagnosis and treatment of infection and bacterial resistance
15.1 Introduction
15.2 Bacterial extracellular vesicles
15.3 Mammalian extracellular vesicles
15.4 Isolation and detection of EVs in microfluidics
15.5 Application of EVs for the treatment of bacterial infection and antibiotic resistance
15.6 Current challenges and future perspectives
15.7 Conclusion
Acknowledgments
References
Chapter 16 Aptamer-based nanomaterials for drug/gene delivery systems and diagnostics to combat microbial infections
16.1 Introduction
16.2 Aptamers – properties and functions
16.3 Applications of aptamers
16.4 Introduction to aptamer-based nanomaterials – production, properties, and examples
16.5 A few examples of aptamer functionalized nanomaterial applications include
16.6 Properties of aptamer-based nanomaterials for drug and gene delivery system
16.7 Current diagnostic tools for identification of microbial infections
16.8 Limitations of currently used diagnostics for detecting microbial infections
16.9 Aptamer-based nanomaterials as efficient tools of diagnosis over traditional tools for combating microbial infections
16.10 Examples of aptamer-based nanomaterials used in combating microbial infections
16.11 Limitations of aptamer-based nanomaterials
16.12 Future directions
Abbreviation
References
Chapter 17 Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections
17.1 Antibodies
17.2 Microbial infections
17.3 Monoclonal antibodies for diagnosis of microbial infections
17.4 MAbs for therapy of microbial infections
17.5 Key challenges and future trends of MAbs
References
Chapter 18 Nanoparticle-based antimicrobial for dental restorative materials
18.1 Introduction
18.2 Challenges in oral biofilm control
18.3 Current dental restorative materials and their limitations of antibiofilm response
18.4 Synthesis and characterization of antibacterial nanoparticles
18.5 Properties displayed by nanoscale structures
18.6 Antimicrobial mechanism: Interactions with pathogenic microorganisms
18.7 Incorporation of antibacterial and remineralizing nanoparticles into dental materials: antibiofilm performance and impact on materials’ properties
18.8 Challenges and future outlooks
References
Chapter 19 Toxicity and biocompatibility of nanomaterials: In vivo studies
19.1 Introduction
19.2 Toxicity of the nanomaterials
19.3 Biocompatibility of nanomaterials
19.4 Conclusion and future remarks
List of abbreviations
References
Chapter 20 Oligonucleotides: A therapeutic approach for tackling antimicrobial resistance
20.1 Introduction
20.2 Antisense mechanisms against the bacterial infections
20.3 Challenges to an antisense approach
20.4 Antibacterial antisense agents
20.5 Antiviral and antiparasitic antisense agents
20.6 Concluding remarks
References
Index

Muthupandian Saravanan

Dr. Muthupandian Saravanan is currently a Professor in the Department of Pharmacology at Saveetha University, SIMATS, Chennai, India. He has a degree in Microbiology from Madurai Kamaraj University and a Doctorate with Specialization in Medical Microbiology and Nanomedicine from Sathyabama University, India. As a Post-Doctoral Researcher at the Hebrew University of Jerusalem, he studied nano-biomaterials and their biomedical applications. He later worked as Associate Professor, under the United Nation Development Program in Department of Medical Microbiology and Immunology at Mekelle University in Ethiopia. He has published papers in high impact journals such as the Lancet and Nature. He has participated in more than 75 national and international conferences and reviewed of more than 100 international peer-reviewed journals. He has served as guest editor/ co-editor for reputed PubMed and Scopus indexed journals. He has received many fellowships and awards, notably the IET- Nanobiotechnology premium Awards in 2019 and 2020.

Affiliations and expertise

Professor, AMR and Nanotherapeutics Lab, Department of Pharmacology Saveetha Institute of Medical and Technical Sciences (SIMATS)

Hamed Barabadi

Hamed Barabadi (PharmD, PhD) works as an assistant professor at the Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sci-ences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 3000 citations and h-index of 38. He has received many awards such as IET—Nanobiotech¬nology Premium Awards two times continuously in the years 2019 and 2020. Dr. Barabadi has been featured among the World’s Top 2% scientists list, according to a Stanford University study 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and a few other prestigious journals. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, antioxidant, etc. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Ebrahim Mostafavi

Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine.

Affiliations and expertise

Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

Thomas J Webster

Thomas J. Webster’s (H index: 107; Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has served as a professor at Purdue (2000–2005), Brown (2005–2012), and Northeastern (2012–2021; serving as Chemical Engineering Department Chair from 2012–2019) Universities and has formed over a dozen companies who have numerous FDA approved medical products currently improving human health. He currently serves as a professor, biomedical engineering, Hebei University of Technology and Professor, Center for Biomaterials, Vellore Institute of Technology. Prof. Webster’s research explores the use of nanotechnology in numerous applications. Specifically, his research addresses the design, synthesis, and evaluation of nanophase materials (i.e., materials with fundamental length scales less than 100 nm) as more effective biomedical materials. He has directed numerous international centers in biomaterials and has graduated over 200 students with over 750 peer-reviewed publications. His research on nanomedicine has received attention in media including MSNBC, NBC Nightly News, PBS DragonFly TV, ABC Nightly News via the Ivanhoe Medical Breakthrough Segment, Fox News, the Weather Channel, NBC Today Show, NBC Nightly News, National Geographic TV series on the future of medicine, ABC Boston, Discovery Channel, and more. His work has been on display at the London and Boston Science Museums. He has helped to organize 27 conferences emphasizing nanotechnology in medicine and has organized over 83 symposia at numerous conferences emphasizing biological interactions with nanomaterials. Prof. Webster has received numerous honors including but not limited to: 2002, Biomedical Engineering Society Rita Schaffer Young Investigator Award; 2003, Outstanding Young Investigator Award Purdue University College of Engineering; 2005, American Association of Nanomedicine Young Investigator Award; 2005, Coulter Foundation Young Investigator Award; 2006, Fellow, American Association of Nanomedicine; 2010, Distinguished Lecturer in Nanomedicine, University of South Florida; 2011, Outstanding Leadership Award for the Biomedical Engineering Society (BMES); 2012, Fellow, American Institute for Medical and Biological Engineering (AIMBE, representing the top 2% of all medical and biological engineers); 2013, Fellow, Biomedical Engineering Society; 2014, Fellow, Ernst Strugmann; 2016, Fellow, College of Fellows of the International Union of Biomaterials Sciences and Engineering; 2016, Wenzhou 580 Award; 2016, Zeijiang 1000 Talent Program; 2016, SCOPUS Highly Cited Research (Top 1% Materials Science); 2016, Hsun Chinese Academy of Sciences Award; 2017, Fellow, National Associate of Inventors; 2017, Acta Biomaterialia Silver Award (given to researchers under the age of 45); 2019, Overseas Fellow, Royal Society for Medicine; 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Mixed Fields); and others.

Affiliations and expertise

Professor, Department of Biomedical Engineering, Hebei University of Technology, Hebei, China and Professor, Center for Biomaterials, Vellore Institute of Technology, Vellore, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Muthupandian Saravanan

Hamed Barabadi

Ebrahim Mostafavi

Thomas J Webster

Related books